Role of the pharmaceutical device Prisma® Skin in modulating fibroblast functions in vivo

Our recent in vitro investigations showed that Prisma® Skin is able to enhance re-epithelialization and granulation processes, acting on human epidermal keratinocytes and dermal fibroblasts. This pharmaceutical device can induce a strong cytoskeletal re-organization to enhance cell migration and invasion.

The aim of this study is to evaluate the clinical effects of Prisma® Skin on patients affected by pressure ulcers focusing on fibroblasts activity.

This clinical study focused on the use of the Prisma® Skin on nine permanently bedded patients. The hematoxylin-eosin and immunohistochemical staining of patients’ biopsies that we assumed as a T0 point proved the lack of cell structure in the analyzed tissues with a tendency to wound bed sclerosis and reduced inflammatory activity.

We performed treatments for 14 days with Prisma® Skin and we found a relevant formation of granulation tissue. The strong increase of vimentin expression confirmed fibroblasts recruitment on patients’ skin biopsies the end of the treatment.

Our clinical study shows the positive effects of Prisma® Skin on pressure ulcers modulating fibroblast functions.

Author: Antonello Petrella, University of Salerno, Italy.

International Conference on Wound Care, Tissue Repair and Regenerative MedicineDate & venue: June 14-15, 2018 | London, UKWebsite:


Popular posts from this blog

Human microbial detection and study

Role of Bacteria in Bowel cancer

Stem Cells : A Shelter for TB